Core Viewpoint - United Imaging Healthcare has been awarded the first prize in the 2024 Shanghai Science and Technology Progress Award for its project on the independent research and industrialization of multimodal molecular imaging equipment, highlighting its technological advancements in the field [1][2]. Group 1: Project Achievements - The project focuses on multimodal molecular imaging systems, including PET/CT and PET/MR, which can non-invasively and accurately detect metabolic information in human tissues, aiding in the early detection and precise diagnosis of major diseases such as tumors and cardiovascular diseases [1]. - The project has achieved 13 national Class III medical device registrations and 12 certifications from the US FDA and EU CE, with over 600 molecular imaging devices installed globally across nearly 30 countries, including China, the US, Japan, Italy, Germany, and France [2]. Group 2: Clinical and Research Collaboration - The company has conducted extensive clinical application validation over the past decade, establishing a clinical and research application system that includes tumor imaging expert consensus and pharmacokinetic studies [3]. - The project has collaborated with ten well-known large hospitals in China, collecting over 40,000 clinical imaging cases for tumors using the world's first Total-body PET/CT uEXPLORER device, which has led to the development of personalized imaging and diagnostic solutions [3].

Core Insights - The project "Independent R&D and Industrialization of Multimodal Molecular Imaging Equipment" by United Imaging Healthcare won the first prize in the 2024 Shanghai Science and Technology Progress Award, highlighting the recognition of the company's achievements in this field [1] - The company aims to enhance product performance and application coverage to improve accessibility to medical services, driven by clinical and research needs [1] Group 1: Project Achievements - The project has led to the development of several world-first and China-first products, filling a significant gap in China's high-end molecular imaging sector [2] - It has elevated China's PET technology to an internationally leading position and fostered the collaborative development of upstream and downstream enterprises in crystal materials [2] - The project has overcome all core technologies in multimodal molecular imaging, achieving breakthroughs in key technologies such as large-size LYSO crystal growth and high-performance digital PET detectors [2] Group 2: Technical Innovations - The molecular imaging team introduced a modular, multi-unit architecture to enable seamless system expansion, supporting large-scale data collection from 560,000 detectors [3] - The sensitivity of the uEXPLORER system was enhanced by 40 times through cross-unit composite technology, and a distributed parallel signal processing architecture based on GPU clusters was implemented to address massive data processing challenges [3] - Image reconstruction time was significantly reduced from one day to 23 minutes, providing substantial technical support for clinical applications [3] Group 3: Market Impact - The project has achieved 13 national Class III medical device registrations and 12 FDA and CE certifications, with over 600 molecular imaging devices installed globally across nearly 30 countries [3] - The PET/CT products have maintained the number one market share in China's molecular imaging market for nine consecutive years, while PET/MR products reached a domestic market share of over 60% in 2022 [3] - The project has successfully reversed the historical reliance on imported nuclear medicine molecular imaging equipment, increasing the domestic production rate of such devices to over 50% [3]